---

For the first time, Medicare is covering certain GLP-1 weight-loss medications for eligible beneficiaries, a significant policy shift that could make highly effective obesity treatments affordable for millions of older Americans.

The new Medicare GLP-1 Bridge program, which launched July 1, allows qualifying Medicare beneficiaries to receive certain GLP-1 medications for a flat $50 monthly copay through the end of 2027. Until now, federal law generally prohibited Medicare from covering drugs prescribed solely for weight loss. 

While the new benefit has generated excitement, obesity specialists at the University of Michigan say beneficiaries should understand its restrictions before assuming they qualify.

---

Not everyone is eligible

The program is available only to people enrolled in Medicare Part D prescription drug coverage, whether through a standalone Part D plan, a Medicare Advantage plan with drug coverage, or certain Medicare Special Needs Plans.

People who receive prescription drug benefits through a former employer or union retiree plan instead of Medicare Part D may not qualify. 

Coverage is limited to beneficiaries who meet specific body mass index (BMI) requirements and other health criteria. Patients must also obtain a prescription from an approved healthcare provider and complete Medicare’s prior authorization process before the medication will be covered. 

Medicare officials emphasize that patients should not expect to walk into a pharmacy and immediately receive the medication. Approval must first be processed through Medicare.

---

Only certain drugs are included

The Bridge program does not cover every GLP-1 medication or every version of eligible drugs.

Currently covered medications include certain forms of Wegovy, Zepbound, and Foundayo. Some formulations remain excluded, so patients should confirm with their physician or pharmacist that the prescribed medication qualifies under the program.

---

That $50 copay comes with a catch

Although the monthly cost is substantially lower than the retail price of GLP-1 medications, the payments are handled outside Medicare Part D’s normal benefit structure.

That means the $50 monthly copay does not count toward a beneficiary’s annual Part D deductible or their out-of-pocket prescription drug spending cap. Likewise, low-income subsidies such as the Extra Help program do not reduce the Bridge program’s $50 monthly charge.

---

The program is temporary

The Bridge demonstration is scheduled to run through Dec. 31, 2027, while the Centers for Medicare & Medicaid Services evaluates its costs and health outcomes. What happens after that remains uncertain and will depend on future federal policy decisions. 

Obesity medicine specialists say the program represents an important recognition that obesity is a chronic disease that can benefit from medical treatment. At the same time, they encourage beneficiaries to discuss eligibility, treatment options, and long-term expectations with their healthcare providers before pursuing coverage.